Formulation and in-vitro evaluation of ketotifen fumarate sustained release matrix tablets using HPMC 4000 cps (methocel K4M CR) and xanthan gum (3:1)
Keywords:
Ketotifen Fumarate, HPMC, Xanthan gum, Matrix tablets, Sustained ReleaseAbstract
The purpose of this research work was to develop oral sustained release matrix tablets using the combination of HPMC 4000 cps (methocel K4M CR) and xanthan gum (3:1), in order to probe the effect of these polymers on release mechanism from matrix tablets. The matrix tablets of Ketotifen fumarate were prepared by direct compression process using methocel K4M CR and xanthan. The dissolution profiles were carried out by USP apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl and distilled water. A One way analysis of variance (ANOVA) was used to interpret the result. Statistically significant differences were found among the drug release profile from different matrices. At a higher polymeric content (70% of the total tablet weight), drug release from the combination of methocel K4M CR and xanthan gum (3:1) was slower. On the contrary, at a lower polymeric level (40% of the total tablet weight), the rate of drug release was prominent. The best-fit release kinetics was accomplished with the Higuchi model followed by the zero-order plot, Korsmeyer and Hixson Crowell equations. One formulation showed drug release is more controlled. The data obtained proved that the formulations are useful for a sustained release of ketotifen fumarate. From these formulations corresponded more controlled of the drug release by the higher polymeric level of methocel K4M CR & xanthan and vice versa. The release of the model drug from the higher combination of methocel K4M CR and xanthan gum matrix tablets was prolonged. As a result, an oral release dosage form to evade the frequency of administration of such type of drug.
References
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004. p. 1712.
Parafitt K., Martindale. The Complete Drug Reference, 32nd edition, London: Royal Pharmaceutical Society, 1999, 755-756.
Novartis Opthalmics. Zaditor (ketotifen fumarate) ophthalmic solution prescribing information. Duluth, GA, 2002 Oct.
Tantichaiyakul P, Preutthipan A. Ketotifen versus inhaled budesonide for controlling childhood asthma. J Med Assoc Thai 2010 may, 93 (5), 541-9
S. Budavari. The Merck Index. 12th ed. Whitehouse Station, NJ: Merck and Co. Inc, 1996, p. 836.
S. M. Grant, K. L. Goa, A. Fitton and E. M. Sorkin, Ketotifen: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Asthma and Allergic Disorders. Drugs, 1990, 40, 412.
I. LE Blaye, B. Donatini, M. Hall and P. Krupp, Acute Ketotifen Overdosage A Review of Present Clinical Experience Drug Saf, 1992, 7, 387
Manuela C. C. M. Sobral, Abilio J. F. N. Sobaral, J. T. Guthrie and M. H. Gil. Ketotifen controlled release from cellulose acetate propionate and cellulose acetate butyrate membranes, 10 July, 2007.
Sujja-areevath, J., Munday D.L., Cox P.J., Khan K.A.: Eur. J. Pharm. Sci, 1998, 6, 207.
Tilak, R., Kanwar M., Lal R., Gupta A.: Drug Dev. Ind. Pharm. 2000, 26, 1025.
Dhopeshwarkar, V. Zatz J.L.: Drug Dev. Ind. Pharm. 1993, 19, 999.
Lordi NG. Sustained release dosage form. In: The Theory and Practice of Industrial Pharmacy, 3rd Ed., Lea & Febiger, Philadelphia, USA, 1986, pp. 430-456.
Colorcon. Methocel Literature, Oral Modified Release System, http://www.colorcon.com/pharma/mod_rel/methocel/index.html, 2005.
Sung KC, Nixon PR, Skoug JW, Roburt Ju T, Gao P, Topp EM and Patel MV (). Effects of formulation variables on drug and polymer release from HPMC based matrix tablets. Int. J. Pharm., 1996, 142, 53-60.
Somade S and Singh KK. Comparative Evaluation of Wet Granulation and Direct Compression Methods for Preparation of Controlled Release Ranitidine HCL Tablets,MayJune:IJPS.http://www.indianpharma.org/journal/index.php/2002/3may%20 %20june/comevaluation.html, 2002.
Talukder MM, Michoel A, Rombaut P and Kinget R. Comaprative study on xanthun gum and hydroxypropyl methyl cellulose as matrices for controlled-release drug delivery. Int. Pharm. 1996, 129, 231-241.
Shato H, Miyagawa, Y, Okabe T, Miyajima M and Sunada H. Dissolution mechanism of Diclofenac from wax matrix granules. J. Pharm. Sci.1997, 86, 929-934.
Mockel JE, Lippold BC. Zero order release from hydrocolloid matrices. Pharm Res. 1993, 10, 1066- 1070.
Hogan J. Hydroxypropylmethylcellulose sustained release technology. Drug Dev IndPharm. 1989, 15, 975-999.
Ebube NK, Hikal A, Wyandt CM, Beer DC, Miller LG, Jones AB. Sustained release of acetaminophen from heterogeneous matrix tablets, influence of polymer ratio, polymer loading and coactive on drugrelease. Pharm Dev Technol. 1997, 2, 161-170.
Gao P., Skoug J. W., Nixon P. R., Ju T. R., Stemm N. L., and Sung K. C. Swelling of hydroxypropyl methylcellulose tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release, J. Pharm. Sci. 1996, 85, 732–740.
Banakar, U. Dissolution of modified-release dosage forms. In: Pharmaceutical dissolution testing, 1st Edn., Marcel-Dekker, Inc., New York, 1992, pp.322.
Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931, 23, 923-931.
